Fabry Disease
New Fabry disease research, summarized each month in plain language.
2026 so far: In the months covered (January 2026 to September 2026), treatment evidence highlighted that biomarker changes did not necessarily match symptom changes (lucerastat) and that real-world add-on signals (SGLT2) were mixed and non-randomized. At the same time, more work supported using combined tests for diagnosis and for tracking heart risk. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Lucerastat trial results. It became clearer that lab marker changes may not match pain changes.
- Migalastat follow-up. Longer observational follow-up added patient-reported and biomarker context.
- Add-on medicines. Early safety reports were followed by mixed and then stronger observational outcome links.
- ERT practical issues. Reports connected immune responses to infusion reactions and highlighted variable organ outcomes.
- Heart monitoring patterns. More studies tied outcomes to combined ECG/imaging signals and progression speed.
New
September 2026
- SGLT2 outcome link. SGLT2 inhibitor use was linked to fewer heart events.
- Heart test changes. ECG changes increased over time more than imaging measures.
- Distinguishing heart causes. ECG plus ultrasound helped separate Fabry from similar conditions.
August 2026
- Infusion reaction risk. A stepwise enzyme start was linked to fewer infusion reactions.
- Heart change speed. Faster heart changes were linked to higher later heart risk.
- When to test. Certain heart and kidney findings helped guide targeted genetic testing.
July 2026
- Kidney treatment timing. Small series linked earlier enzyme therapy to steadier kidney function.
- Heart test changes. Some ECG measures shifted with more advanced heart involvement.
- Genetic test results. High-risk screening often found gene changes not clearly disease-causing.
- Lab marker limits. Markers tended to match specific organ changes, not overall activity.
June 2026
- Kidney course varies. Kidney outcomes varied widely, even among relatives.
- Enzyme therapy markers. Blood storage markers often fell, but organ outcomes varied.
- Heart risk tracking. Imaging, rhythm tests, and genetics together estimated heart risk.
- Unclear gene variants. Newborn screening found many gene variants with unclear meaning.
May 2026
- Migalastat follow-up. In people with amenable variants, lyso-Gb3 in blood tended to decrease and kidney and heart measures were often stable over follow-up.
- Add-on medicines. Small studies of add-on medicines left kidney (protein in urine) and heart effects uncertain.
- Heart rhythm risk. Older age and short runs of fast ventricular rhythm were linked with higher risk of major rhythm events.
- Newborn screening gaps. Enzyme-only newborn screening could miss some females unless cutoffs are adjusted or DNA testing is added.
April 2026
- Treatment over 2 years. In one observational study, many people reported that perceived treatment benefit stayed similar over about two years.
- Heart risk markers without heart biopsy. Heart MRI measures and skin biopsy findings were linked with markers of heart risk in Fabry disease.
- Antibodies that reduce enzyme activity. In lab tests, some people’s antibodies reduced the activity of infused enzyme, and patterns differed by sex and by ERT product.
- Newborn screening: earlier, but often unclear. Newborn screening identified Fabry earlier, but many results were hard to interpret and needed careful follow-up.
March 2026
- SGLT2 add-on safety. In one real-world group, adding an SGLT2 inhibitor on top of Fabry-specific therapy appeared safe over 12 months.
- Interpreting heart scans. Some heart imaging patterns seen in Fabry disease can also appear in other conditions, so results need clinical context.
- Enzyme test interference. Some medicines (including migalastat) and some lab methods can affect enzyme test results unless the testing approach accounts for them.
- Early inflammation signals. In a screened group of boys, some inflammation-related signals were reported before symptoms appeared.
February 2026
- Genetic and family testing. In high-risk women, genetic testing identified more Fabry cases than enzyme-only screening, and cascade testing in families repeatedly accounted for many diagnoses in girls and children.
- Kidney add-on reports. In a small observational report, adding dapagliflozin to stable Fabry-specific therapy was linked with lower urine albumin, and a single-patient report described similar stabilization of kidney lab measures with another add-on approach.
- Predicting heart and stroke events. In one large cohort, serious heart or stroke events occurred in a minority and were more common in males, with higher risk linked to older age and routine measures such as kidney filtration and ECG QRS.
January 2026
- Biomarkers vs pain. In a 6‑month placebo‑controlled trial, lucerastat lowered Fabry storage markers in blood and urine but did not reduce neuropathic pain, separating lab changes from symptom changes.
- Missed genetic causes. Long‑read genetic testing found large non‑coding GLA insertions in two people with Fabry‑like biochemical findings, showing one specific way standard genetic tests can miss a cause.
- New monitoring tools. Studies tested new ways to measure Fabry features, such as retinal vessel measurements and a kidney biopsy image score, but most tools are still being validated across settings.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Fabry disease update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).